AstraZeneca: lymphoma drug gets breakthrough designation.
(CercleFinance.com) - AstraZeneca said on Tuesday that its oncology drug Acalabrutinib, developed by its unit Acerta Pharma, has received a breakthrough therapy designation from the US Food and Drug Administration.
AstraZeneca and its haematology division today announced that the FDA has granted its breakthrough therapy designation for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
"This is an exciting regulatory milestone for our work in haematology," said Acerta Pharma chief executive officer Flavia Borellini.
After AstraZeneca acquired a majority stake interest in the firm, Acerta Pharma serves as the biopharmaceutical company's hematologic oncology center of excellence.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
AstraZeneca and its haematology division today announced that the FDA has granted its breakthrough therapy designation for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
"This is an exciting regulatory milestone for our work in haematology," said Acerta Pharma chief executive officer Flavia Borellini.
After AstraZeneca acquired a majority stake interest in the firm, Acerta Pharma serves as the biopharmaceutical company's hematologic oncology center of excellence.
Copyright (c) 2017 CercleFinance.com. All rights reserved.